May 26, 2009 – The Medical Imaging and Technology Alliance said today a recent study conducted by researchers at the University of Pennsylvania confirms computed tomography angiography (CTA) to be a safe, effective and cost-efficient means of ruling out cardiovascular disease in patients presenting to the emergency room with chest pain. The results of this landmark study were presented at the
Medical Education Technologies (METI) offers its Human Patient Simulators for medical education programs, allowing learners to develop a high level of confidence and, ultimately, a demonstration of competence.
The virtual-reality CathLabVR System by Immersion Medical fills roughly the same space as real cath lab equipment. It includes two monitors. One displays fluoroscopic views, virtual assistant functions, navigation control, and simulated patient information. The other is for displaying physio, cine, and still images.
The new and enhanced VIST Enhanced Carotid and Coronary 7.7 training modules feature vital signs, complications, medication management and measurement functionality enhance to create clinical realism and elevate the educational value of simulation training. The system includes new patient cases, including chronic total occlusion and transradial access.
May 26, 2009 – AMG International GmbH last week submitted its second-generation drug-eluting stent (DES), Itrix, for regulatory review in Europe. The stent offers a bioabsorbable polymer that holds the drug.
May 26, 2009 – Biotronik Inc. recently launched its Lumax 540 series implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillator (CRT-D) devices during Heart Rhythm 2009.
May 26, 2009 – Medtronic intends to seek FDA approval for the use of cardiac resynchronization therapy (CRT) in certain mildly symptomatic heart failure patients.
While CRT is a proven life-saving therapy for some patients with advanced stages of heart failure (New York Heart Association Class III, IV), it is not currently approved for use in earlier stages, or mildly symptomatic patients.
May 26, 2009 - United Therapeutics Corp. said today the FDA approved ADCIRCA (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).
